Mckesson Corporation · NYSE:MCK
Mckesson — Non-Deal Roadshow (July 2021)
14 slides from Mckesson's roadshow presentation, Jul 12, 2021
Slide 1: Summer 2021 Virtual Roadshow: Shareholder Engagement Program
Summer 2021 | Virtual Roadshow McKesson Corporation Shareholder Engagement Program
Slide 2: McKesson At a Glance
McKesson At a Glance As of March 31, 2021. Delivering 1/3 of all prescription medicines in North America #1 distributor in community oncology and key specialties Delivering medical-surgical supplies and services to 275,000+ customers >10,500 owned and banner pharmacies across Canada and Europe US On
Slide 3: Focus on Executing on Strategic Priorities; Fiscal Year 2021 Operating Results
*As of March 31, 2021. Please see Appendix A for an explanation of non-GAAP measures and a reconciliations to GAAP, and slides 6 and 7 for additional detail on GAAP-only pre-tax charge related to the estimated liability for opioid-related claims of governmental entities (“the settlement charge”). Ag
Slide 4: Fighting the COVID-19 Pandemic
Fighting the COVID-19 Pandemic Vaccine Support Expanded our partnership with the CDC for the distribution of certain pandemic vaccines to support the U.S. government as a centralized distributor of COVID-19 vaccines Partnered with the Department of Health and Human Services and Pfizer to manage the
Slide 5: Our Continued Efforts to Address the Opioid Epidemic
Our Continued Efforts to Address the Opioid Epidemic Highlights from McKesson’s Controlled Substance Monitoring Program (CSMP)* Experienced CSMP team Team comprised of >70 members in Reg. Affairs with 290+ years of cumulative DEA and DOJ law enforcement experience, including experts in retail pharma
Slide 6: Board Considered the Settlement Charge When Determining Compensation Outcomes
Board Considered the Settlement Charge When Determining Compensation Outcomes Each year the Compensation Committee evaluates our compensation program and incentive programs in the broader context of performance, and other events and issues that have an impact on our Company Although a settlement has
Slide 7: Board Reduced Compensation of Current Executives Due to Settlement Charge
In light of the factors considered, the scale of the adjustment and the potential future actual cost associated with the settlement charge, the Compensation Committee determined that it was appropriate to reduce payouts under the FY 2021 MIP and FY 2019 – 2021 Cash LTIP for our NEOs, as illustrated
Slide 8: Board Reduced Compensation of Former Executives Due to Settlement Charge
As part of the settlement considerations and our pay for performance philosophy, our Compensation Committee reflected on the roles of the NEOs during the period covered by allegations in the litigation In addition to the reduced payments for current NEOs, the Committee determined to reduce the payou
Slide 9: Executive Compensation Pay Elements and Metrics
Pay Element FY 2021 Metric Weight Rationale Base Salary -- -- Attracts and retains high-performing executives by providing market-competitive fixed pay Management Incentive Plan Adjusted EPS 50% Rewards operational performance and profitability; important driver of share price valuation and sharehol
Slide 10: Governance and Shareholder Engagement Highlights
Independent board chair Director tenure policy to go into effect in 2022 8 of 9 directors are independent Board of Directors Right to call special meeting of shareholders (15%) Proxy access No supermajority vote provisions Shareholder Rights Pay for performance alignment Robust senior management suc
Slide 11: Our Holistic Approach to Sustainability and ESG
Our Holistic Approach to Sustainability and ESG Source: McKesson’s FY 2020 Corporate Responsibility Report. As a global healthcare company, delivering better health outcomes for our employees, our communities, and our environment is our mission. Every day, we strive to inspire and enable people to r
Slide 12: Our Directors' Backgrounds Contribute to an Effective and Well-Balanced Board
Our Directors’ Backgrounds Contribute to an Effective and Well-Balanced Board Edward A. Mueller (Independent Chair) Retd. Chairman & CEO, Qwest Communications International Brian S. Tyler (Chief Executive Officer) CEO, McKesson Corporation Dominic J. Caruso Retd. EVP & CFO, Johnson & Johnson Joined
Slide 13: We Request Your Support
We Request Your Support 1. Election of 9 Directors for a One-Year-Term 2. Ratification of Appointment of the Independent Registered Public Accounting Firm 3. Non-Binding Advisory Vote on Executive Compensation 4. Shareholder Proposal on Action by Written Consent of Shareholders Items Your Board’s Re
Slide 14: Appendix A Cautionary Statement
Appendix A Cautionary Statement Except for historical information contained in this presentation, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks a